Robocast Zn- and Co-doped bioactive glass/tricalcium phosphate scaffolds for bone regeneration
Monfared MH., Mohandesnezhad S., Azami M., Samani S.
Laboratory Study, published in J Biol Eng (2025) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Laboratory Study
- Journal
- J Biol Eng (2025)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 41353425
- PMCID
- PMC12817833
- DOI
- 10.1186/s13036-025-00585-x
Abstract (original English)
BACKGROUND: Bone tissue engineering requires scaffolds that synergize mechanical strength with bioactivity. This study aimed to develop and characterize 3D-printed zinc (Zn)- and cobalt (Co)-doped 45S5 bioactive glass (BG)/β-tricalcium phosphate (TCP) composite scaffolds for enhanced bone regeneration. METHODS: Sol-gel-synthesized BG powders, doped with 3–15% Zn or 1–5% Co, were combined with TCP (50:50 ratio) to fabricate porous scaffolds via robocasting. Scaffolds were screened for cytocompatibility (MTT assay) and ion release (ICP-OES). The optimal compositions (3% Zn and 1% Co) were characterized for mechanical strength, in vitro bioactivity in SBF, and osteogenic potential using hADMSCs through qPCR, ALP activity, immunocytochemistry, and Alizarin Red staining. RESULT: The 3% Zn- and 1% Co-doped scaffolds demonstrated excellent cytocompatibility (≥ 90% hADMSC viability) with controlled ion release. They exhibited compressive strengths of 15.67–20.24 MPa, matching cancellous bone, and significantly accelerated hydroxyapatite formation in SBF. Biologically, the scaffolds induced distinct, stage-specific osteogenic responses. Zn-doping preferentially enhanced early osteogenesis, marked by significantly higher collagen type I (COL-1) expression at day 21 and the highest ALP activity at day 14. In contrast, Co-doping specifically promoted late-stage maturation, resulting in sup
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.